# HengDong Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hengdong-biotechnology

- Industry: Pharmaceuticals
- Headquarters: Zhongshan, China
- Latest round: Series A (Nov 11, 2025)
- Investors on record: 4

## About

Established in 2021 and based in Zhongshan, China, HengDong Biotechnology dedicated to the development of agonistic antibody drugs with class I drug potential using the company's advanced and proprietary core technology platform for screening, optimization and evaluation of agonistic antibodies. Currently, the company has laid out several pipelines, of which the most leading pipeline will be declared IND in 2023. In November 2025, HengDong Biotechnology raised a series A funding from new investor Zhongshan Torch Development Area Science Innovation Industrial Capital.

The company has created a biotechnology platform for developing agonistic antibody drugs and developed agonistic antibodies with mono- and dual-antibody forms, which not only achieve an order of magnitude increase in agonistic activity, but also enhance tumor tissue targeting.

The company generates revenue from developing agonist antibody drugs.

## Funding rounds

- Series A, Nov 11, 2025 — Zhongshan Torch Electronics Industry Fund Management
- Angel, Aug 8, 2022 — Tengye Ventures, National Health Technology Park, Zhongshan Qingyun Technology Partnership

## Investors

- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Angel
- National Health Technology Park — Angel
- Zhongshan Qingyun Technology Partnership — Angel
- Zhongshan Torch Electronics Industry Fund Management (https://capitalatlas.ai/funds/zhongshan-torch-electronics-industry-fund-management) — Series A